{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:34:16Z","timestamp":1761284056694,"version":"build-2065373602"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06455-2","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T06:44:25Z","timestamp":1758177865000},"page":"4515-4524","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival analysis and prognosis model construction of elderly patients with acute promyelocyticleukemia: a retrospective study based on SEER database"],"prefix":"10.1007","volume":"104","author":[{"given":"Jinhong","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifen","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingmu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"issue":"1","key":"6455_CR1","doi-asserted-by":"publisher","first-page":"2293513","DOI":"10.1080\/16078454.2023.2293513","volume":"29","author":"L Liu","year":"2024","unstructured":"Liu L et al (2024) Prognosis influence of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia with t(15;17)(q24;q21). Hematology 29(1):2293513","journal-title":"Hematology"},{"issue":"4","key":"6455_CR2","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1016\/j.clml.2019.12.011","volume":"20","author":"RP Yedla","year":"2020","unstructured":"Yedla RP et al (2020) Outcomes in adult acute promyelocytic leukemia: a decade experience. Clin Lymphoma Myeloma Leuk 20(4):e158\u2013e164","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"6455_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"8","key":"6455_CR4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jgo.2020.03.019","volume":"11","author":"HD Klepin","year":"2020","unstructured":"Klepin HD et al (2020) Treatment of acute promyelocytic leukemia in older patients: recommendations of an International Society of Geriatric Oncology (SIOG) task force. J Geriatr Oncol 11(8):1199\u20131209","journal-title":"J Geriatr Oncol"},{"issue":"11","key":"6455_CR5","doi-asserted-by":"publisher","first-page":"992","DOI":"10.18632\/oncotarget.27513","volume":"11","author":"JJ Jimenez","year":"2020","unstructured":"Jimenez JJ et al (2020) Acute promyelocytic leukemia (APL): a review of the literature. Oncotarget 11(11):992\u20131003","journal-title":"Oncotarget"},{"issue":"1","key":"6455_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1182\/hematology.2023000477","volume":"2023","author":"O Odetola","year":"2023","unstructured":"Odetola O, Tallman MS (2023) How to avoid early mortality in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2023(1):248\u2013253","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"6455_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cncr.33933","volume":"128","author":"HM Kantarjian","year":"2022","unstructured":"Kantarjian HM et al (2022) The cure of leukemia through the optimist\u2019s prism. Cancer 128(2):240\u2013259","journal-title":"Cancer"},{"issue":"1","key":"6455_CR8","first-page":"52","volume":"26","author":"LW Fang","year":"2018","unstructured":"Fang LW et al (2018) Analysis of early-death and factors affecting prognosis of patients with acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 26(1):52\u201357","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"6455_CR9","first-page":"169","volume":"18","author":"GS Guru Murthy","year":"2020","unstructured":"Guru Murthy GS et al (2020) Improving outcomes of acute promyelocytic leukemia in the current era: analysis of the SEER database. J Natl Compr Canc Netw 18(2):169\u2013175","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"6455_CR10","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.clml.2021.07.023","volume":"22","author":"Y Tao","year":"2022","unstructured":"Tao Y et al (2022) Differential survival outcomes between de novo and secondary acute promyelocytic leukemia: an updated population-based study. Clin Lymphoma Myeloma Leuk 22(1):e7\u2013e14","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6455_CR11","doi-asserted-by":"crossref","unstructured":"Yin XJ et al (2023) At what point are long-term (>\u20095 Years) survivors of APL safe? A study from the SEER database. Cancers (Basel)\u00a015(3)","DOI":"10.3390\/cancers15030575"},{"issue":"1","key":"6455_CR12","first-page":"50","volume":"10","author":"WQ Che","year":"2023","unstructured":"Che WQ et al (2023) How to use the Surveillance, Epidemiology, and End Results (SEER) data: research design and methodology. Mil Med Res 10(1):50","journal-title":"Mil Med Res"},{"key":"6455_CR13","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jpeds.2020.04.007","volume":"223","author":"R Venkitachalam","year":"2020","unstructured":"Venkitachalam R, Szabo A, Guru Murthy GS (2020) Population-level outcomes of pediatric acute promyelocytic leukemia in the United States. J Pediatr 223:114-119.e5","journal-title":"J Pediatr"},{"issue":"2","key":"6455_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/10428194.2018.1492126","volume":"60","author":"E Borlenghi","year":"2019","unstructured":"Borlenghi E et al (2019) Acute promyelocytic leukemia in patients aged > 70 years is not rare and highly curable: a single center series of 21 unselected patients. Leuk Lymphoma 60(2):531\u2013534","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"6455_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminhematol.2018.07.004","volume":"56","author":"HJ Iland","year":"2019","unstructured":"Iland HJ (2019) Curative strategies in APL. Semin Hematol 56(2):131\u2013138","journal-title":"Semin Hematol"},{"issue":"2","key":"6455_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/17474086.2019.1562332","volume":"12","author":"M Breccia","year":"2019","unstructured":"Breccia M, Fo\u00e0 R (2019) Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia. Expert Rev Hematol 12(2):81\u201387","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"6455_CR17","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1007\/s00277-022-04954-0","volume":"101","author":"M Yanada","year":"2022","unstructured":"Yanada M (2022) Treatment for relapsed acute promyelocytic leukemia. Ann Hematol 101(12):2575\u20132582","journal-title":"Ann Hematol"},{"issue":"2","key":"6455_CR18","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00432-019-03076-x","volume":"146","author":"B Jin","year":"2020","unstructured":"Jin B et al (2020) Comparative analysis of causes and predictors of early death in elderly and young patients with acute promyelocytic leukemia treated with arsenic trioxide. J Cancer Res Clin Oncol 146(2):485\u2013492","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"6455_CR19","first-page":"e2035","volume":"7","author":"K Langdon","year":"2024","unstructured":"Langdon K, Cosentino S, Wawryk O (2024) Superiority of anthracycline-free treatment in standard-risk acute promyelocytic leukemia: a systematic review and comparative epidemiological analysis. Cancer Rep (Hoboken) 7(3):e2035","journal-title":"Cancer Rep (Hoboken)"},{"issue":"11","key":"6455_CR20","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1080\/0284186X.2021.1971291","volume":"60","author":"S Rosati","year":"2021","unstructured":"Rosati S et al (2021) Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta Oncol 60(11):1520\u20131526","journal-title":"Acta Oncol"},{"issue":"11","key":"6455_CR21","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.3324\/haematol.2018.193151","volume":"103","author":"R Rahm\u00e9","year":"2018","unstructured":"Rahm\u00e9 R et al (2018) Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial). Haematologica 103(11):e519\u2013e521","journal-title":"Haematologica"},{"issue":"4","key":"6455_CR22","doi-asserted-by":"publisher","first-page":"T69","DOI":"10.1530\/JME-22-0141","volume":"69","author":"V Korsos","year":"2022","unstructured":"Korsos V, Miller WH Jr (2022) How retinoic acid and arsenic transformed acute promyelocytic leukemia therapy. J Mol Endocrinol 69(4):T69-t83","journal-title":"J Mol Endocrinol"},{"key":"6455_CR23","doi-asserted-by":"publisher","first-page":"1062524","DOI":"10.3389\/fonc.2022.1062524","volume":"12","author":"SG Iyer","year":"2022","unstructured":"Iyer SG et al (2022) The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. Front Oncol 12:1062524","journal-title":"Front Oncol"},{"issue":"2","key":"6455_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14740\/jh773","volume":"10","author":"N Zapata-Canto","year":"2021","unstructured":"Zapata-Canto N et al (2021) Acute promyelocytic leukemia: a long-term retrospective study in Mexico. J Hematol 10(2):53\u201363","journal-title":"J Hematol"},{"issue":"11","key":"6455_CR25","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1080\/10428194.2019.1607327","volume":"60","author":"O Salamero","year":"2019","unstructured":"Salamero O et al (2019) Real life outcomes of patients aged \u2265 75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leuk Lymphoma 60(11):2720\u20132732","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"6455_CR26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/leu.2017.178","volume":"32","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2018","unstructured":"Mart\u00ednez-Cuadr\u00f3n D et al (2018) Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy. Leukemia 32(1):21\u201329","journal-title":"Leukemia"},{"issue":"10","key":"6455_CR27","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1007\/s00277-021-04620-x","volume":"100","author":"K Matsuda","year":"2021","unstructured":"Matsuda K et al (2021) Risk factors for early in-hospital death in patients who developed coagulopathy during induction therapy for acute promyelocytic leukemia: a nationwide analysis in Japan. Ann Hematol 100(10):2613\u20132619","journal-title":"Ann Hematol"},{"key":"6455_CR28","doi-asserted-by":"crossref","unstructured":"Hermsen J, Hambley\u00a0B (2023) The coagulopathy of acute promyelocytic leukemia: an updated review of pathophysiology, risk stratification, and clinical management. Cancers (Basel) 15(13)","DOI":"10.3390\/cancers15133477"},{"key":"6455_CR29","doi-asserted-by":"crossref","unstructured":"Kayser S, Conneely SE (2023) Management of acute promyelocytic leukemia at extremes of age. Cancers (Basel)\u00a015(14)","DOI":"10.3390\/cancers15143637"},{"key":"6455_CR30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2147\/CIA.S369657","volume":"17","author":"Z Liu","year":"2022","unstructured":"Liu Z et al (2022) Preoperative transthoracic echocardiography predicts cardiac complications in elderly patients with coronary artery disease undergoing noncardiac surgery. Clin Interv Aging 17:1151\u20131161","journal-title":"Clin Interv Aging"},{"issue":"3","key":"6455_CR31","doi-asserted-by":"publisher","first-page":"152804","DOI":"10.1016\/j.imbio.2024.152804","volume":"229","author":"S Pan","year":"2024","unstructured":"Pan S et al (2024) Increased co-expression of ICOS and PD-1 predicts poor overall survival in patients with acute myeloid leukemia. Immunobiology 229(3):152804","journal-title":"Immunobiology"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06455-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06455-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:37Z","timestamp":1761283837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06455-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6455"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06455-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"9 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}